AK104 with chemo before and after surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies AK104 along with chemotherapy given before surgery and after surgery for people with resectable (operable) stage II to IIIA non-small cell lung cancer. It aims to improve treatment effectiveness by shrinking the tumor before surgery and helping prevent it from coming back afterward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer is non-small cell type only (not mixed with small cell).
- You have not been treated yet and your diagnosis is confirmed by pathology.
- Your lung cancer is stage II to IIIA and is planned for surgery (resectable).
- Your body function status is good (ECOG score 0 or 1).
- Your doctors can measure at least one visible tumor spot on scans.
- You have enough organ function for chemotherapy and AK104 (kidney/liver/blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
This trial tests a new drug called AK104, which helps the immune system fight cancer, combined with chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this combination can shrink tumors enough to make surgery more successful.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.